Is AN2 Therapeutics, Inc. (ANTX) a Buy, Sell, or Hold?
AN2 Therapeutics, Inc.
NASDAQ:ANTX
$4.6065 USD
-$0.15 (-3.22%)
- Volume
- 70.21K
- Average Volume
- 325.4K
- Market Capitalization
- $126.23M
- P/E Ratio
- -4.19
- Dividend Yield
- 0.00%
- Price Target
- $9.00
- Year High
- $6.91
- Year Low
- $1.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $15.73
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Eric E. Easom |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ANTX |
| CUSIP | 037326105 |
| CIK | 0001880438 |
| Web | https://www.an2therapeutics.com |
| Phone | 650-331-9090 |
| Currency | USD |
| Employees | 21 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 15.73 |
| Quick Ratio | 15.73 |
| Cash Ratio | 9.62 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.92 |
| Price / Cash Flow | -4.04 |
| Price / Book | 1.92 |
Price Target and Rating
| Average Stock Price Forecast | $9.00 |
| High Stock Price Forecast | $9.00 |
| Low Stock Price Forecast | $9.00 |
| Forecast Upside/Downside | -48.82% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 8 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.16 |
| Trailing P/E Ratio | -4.19 |
| PEG Ratio | -0.13 |
| P/E Growth | -0.13 |
| Net Income | $-35.17M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -52.35% |
| Return on Assets | -39.49% |
Financials Score
| AltmanZ Score | 8.92 |
| Piotroski Score | 2.00 |
| Working Capital | 81.93M |
| Total Assets | 87.49M |
| Ebit | -35.85M |
| Market Cap | 125.78M |
| Total Liabilities | 5.73M |
Poll Results
About AN2 Therapeutics, Inc. (NASDAQ:ANTX) Stock
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California. ...
2026-06-17 12:30:08
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
2026-06-04 07:00:00
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company's oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) caused by infection with the parasite T. cruzi. Key findings from the two studies: In NHPs with naturally acquire.
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
2026-05-21 07:00:00
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 12:50 PM ET, and members of management will be available for 1x1 meetings. A webcast can be accessed on the Investors section of the AN2 Therapeutics we.
2026-05-11 16:01:00
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the first quarter ended March 31, 2026. “This was an important quarter for AN2 as we announced an exciting new program in polycythemia vera that is planned to enter Phase 2 development in the third quarter of 2026. This pr.
AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
2026-05-07 16:01:00
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026 at 4:00 PM ET, and members of management will be available for 1x1 meetings. A webcast can be accessed on the Investors section of t.
Frequently Asked Questions
-
What is the current AN2 Therapeutics, Inc. (ANTX) stock price?
-
AN2 Therapeutics, Inc.(NASDAQ:ANTX) stock price is $4.6065 in the last trading session. During the trading session, ANTX stock reached the peak price of $6.91 while $1 was the lowest point it dropped to. The percentage change in ANTX stock occurred in the recent session was --3.22% while the dollar amount for the price change in ANTX stock was -$-0.15.
-
ANTX's industry and sector of operation?
-
The NASDAQ listed ANTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ANTX?
-
Sanjay Chanda | Chief Development Officer
Sarah Williams | Vice President of Controller & Principal Accounting Officer
Michael R. K. Alley | Co-Founder, Senior Vice President of Research Fellow & Head of Biology
Joseph S. Zakrzewski | Co-Founder & Independent Director
Vince Hernandez | Senior Vice President of Research & Head of Chemistry -
How many employees does ANTX have?
-
Number of ANTX employees currently stands at 21. ANTX operates from 1800 El Camino Real, Menlo Park, CA 94027, US.
-
Link for ANTX official website?
-
Official Website of ANTX is: https://www.an2therapeutics.com
-
How do I contact ANTX?
-
ANTX could be contacted at phone #650-331-9090 and can also be accessed through its website. ANTX operates from 1800 El Camino Real, Menlo Park, CA 94027, US.
-
How many shares of ANTX are traded daily?
-
The average number of ANTX shares traded daily for last 3 months was 325.4K.
-
What is the market cap of ANTX currently?
-
The market value of ANTX currently stands at $126.23M with its latest stock price at $4.6065